Mesothelioma treatment delays that happened because of the COVID-19 pandemic will probably impact survival rates for some patients. A new study of Canadian lung cancer patients found that more than half of them stopped or delayed treatment because of concerns about the virus this spring. Pleural mesothelioma is a lung-related cancer. Like lung cancer patients, mesothelioma patients face a higher risk of virus-related complications because they already have breathing problems. But mesothelioma is also a fast-growing cancer. Most patients get several kinds of treatment at the same time. Mesothelioma treatment delays may give tumors a chance to grow unchecked. A Catch-22 for Mesothelioma Patients Mesothelioma patients and others with lung diseases have had to make some difficult decisions because of … Continue reading Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
A pair of researchers in New Zealand say the typical number of in-person medical appointments for people with untreatable pleural mesothelioma may be more stressful than helpful. Their study focused on lung cancer and pleural mesothelioma patients with no active treatment options. They found that what most of these patients really want is reliable information, hope, and a positive relationship with their medical team. The report suggests that doctors could meet many of these with fewer visits or virtual medical appointments. Coping with Advanced Mesothelioma Malignant pleural mesothelioma is a rare but highly aggressive lung-related cancer. Mesothelioma starts on the lining around the lungs. It can quickly spread into the lungs and to other organs in the chest. Most patients … Continue reading Medical Appointments for Advanced Mesothelioma Patients: How Much is Too Much?
Doctors at the University of Connecticut may have found a way to influence the effectiveness of immunotherapy by manipulating the body’s fight or flight response. The finding could have a bearing on the treatment of advanced mesothelioma. Researchers used mice to confirm the connection between the sympathetic nervous system and the body’s ability to fight off cancer. The sympathetic nervous system regulates the “fight or flight” response to stress. The report shows that this response impacts the development of natural killer cells. Drugs that alter that response might change the effectiveness of immunotherapy. What is the Sympathetic Nervous System? When the body is under stress, the sympathetic nervous system (SNS) releases a cascade of hormones and chemicals. These hormones increase … Continue reading Manipulating “Fight or Flight” Could Impact Effectiveness of Immunotherapy for Mesothelioma
There is hope that a new lung cancer trial combining Keytruda and Tumor Treating Fields could lead to a new treatment for pleural mesothelioma. Recent studies show Keytruda (pembrolizumab) is one of the most promising immunotherapy drugs against malignant mesothelioma. Electrical device Tumor Treating Fields is only the second treatment to receive FDA approval for mesothelioma. This summer, the manufacturers of these two treatments announced they would team up. They will test Keytruda and Tumor Treating Fields in patients with non-small cell lung cancer. The results could impact the future of mesothelioma treatment, too. Two Promising Therapies: Keytruda Keytruda is an immunotherapy drug. It blocks a protein called PD-1. Many types of cancer cells overproduce PD-1 to evade the immune … Continue reading Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?
A new report suggests an anti-malaria drug called quinacrine has potential as a new pleural mesothelioma treatment. Before chloroquine became more popular, quinacrine was widely used to treat malaria. Now doctors mostly use it for a diarrhea disease caused by a parasite. But a report published in the International Journal of Molecular Science says quinacrine also has anti-cancer properties. Laboratory tests suggest it has the makings of a powerful new pleural mesothelioma treatment. The Challenge of Pleural Mesothelioma Malignant mesothelioma starts on the membranes around internal organs. It can quickly spread to other parts of the body. Pleural mesothelioma grows on the lining around the lungs. It is almost always caused by exposure to asbestos dust. Most people with mesothelioma … Continue reading Could Anti-Malaria Drug Become New Pleural Mesothelioma Treatment?
A new report suggests that pleural mesothelioma rates will continue to decline worldwide over the next decade as many countries get wise to the dangers of asbestos. The report comes on the heels of another study showing dramatic declines in US lung cancer deaths. The report on mesothelioma rates comes from market research website, Research and Markets. The company evaluated malignant pleural mesothelioma incidence in seven countries to come up with an 11-year forecast. According to the research, the US, UK, Japan, and four European countries can expect declining rates of asbestos cancer through 2030. Those who do receive a pleural mesothelioma diagnosis may benefit from some of the same drugs that are helping lung cancer patients survive. Lung Cancer … Continue reading Pleural Mesothelioma Rates Expected to Decline Just as Lung Cancer Deaths Have
The first four mesothelioma patients treated with a new kind of T-cell immunotherapy have responded well with few side effects. That is the word from researchers working with the drug TC-210. TC-210 is a type of T cell therapy. It is made by TCR² Therapeutics. Malignant mesothelioma is one of several kinds of cancers that overproduce the protein mesothelin. In the Phase I trial, tumors regressed in all five cancer patients who received T-cell immunotherapy with TC-210. Targeting Cancer with T-Cells T-cells are immune system cells that help fight cancer and other invaders. Mesothelioma and other cancers have ways of avoiding the body’s natural killer T-cell response. T-cell immunotherapy helps to turn it back on. TC-210 is like a “living … Continue reading T-Cell Immunotherapy Trial Could be Good News for Mesothelioma Patients
If you are at risk for malignant mesothelioma, you may want to think twice about taking low dose aspirin on a regular basis. A new study suggests that low dose aspirin could speed up the growth and spread of cancer cells in older people. The study appears in the Journal of the National Cancer Institute. It involved more than 19,000 people in Australia and the US. Low Dose Aspirin and Mesothelioma Many older people take small daily doses of aspirin to reduce their risk for heart attack. Aspirin reduces inflammation and the blood’s ability to clot. This makes it less likely to form the blockages that cause heart attacks and strokes. But mounting evidence suggests that taking low dose aspirin … Continue reading Low Dose Aspirin Could Increase Mesothelioma Risk
Scientists in Vienna are developing a new treatment for a particularly aggressive form of pleural mesothelioma. This form of mesothelioma occurs in people with a genetic mutation. The mutation produces signals that fuel tumor growth. These patients typically have an even worse prognosis than other mesothelioma patients. But the Austrian team came up with a way to block activation of the mutated gene. If the gene does not send its signal, this aggressive form of pleural mesothelioma may grow more slowly. Aggression Fueled by Telomerase Malignant mesothelioma is one of the most aggressive kinds of cancer. It starts on the membranes around organs and can quickly spread to other parts of the body. By the time most people notice symptoms, … Continue reading Gene Targeting Slows Aggressive Form of Pleural Mesothelioma
Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma. All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004. But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma. Checkpoint Inhibitors for Mesothelioma Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma. But this approach does … Continue reading Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care